MedPath
Found 5 clinical trials|View Analysis
Sort by:

Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas

Phase 2
Recruiting
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
First Posted Date
2024-08-16
Last Posted Date
2024-12-06
Lead Sponsor
Institut Claudius Regaud
Target Recruit Count
86
Registration Number
NCT06557889
Locations
🇫🇷

Chu Bordeaux - Hopital Saint André, Bordeaux, France

🇫🇷

Chu Limoges, Limoges, France

🇫🇷

Centre Hospitalier Regional de Marseille, Marseille, France

and more 4 locations

PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC

Early Phase 1
Completed
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Drug: TAK-676
Drug: Carboplatin
Drug: 5-FU
Drug: Paclitaxel
Combination Product: TAK-676 + Carboplatin
Combination Product: Carboplatin + Paclitaxel
Combination Product: Carboplatin + 5-FU
Combination Product: TAK-676 + Carboplatin + 5-FU
Combination Product: TAK-676 + Carboplatin + Paclitaxel
First Posted Date
2023-10-02
Last Posted Date
2023-10-06
Lead Sponsor
Presage Biosciences
Target Recruit Count
15
Registration Number
NCT06062602
Locations
🇺🇸

LSU Health Sciences Center - Shreveport, Shreveport, Louisiana, United States

🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

🇺🇸

University of Cincinnati Health, Cincinnati, Ohio, United States

and more 1 locations

Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck(R/M SCCHN)

First Posted Date
2019-02-26
Last Posted Date
2019-10-30
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
334
Registration Number
NCT03855384
Locations
🇨🇳

Shanghai East Hospital, Shanghai, Shanghai, China

Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC

Phase 2
Completed
Conditions
Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Interventions
First Posted Date
2013-05-30
Last Posted Date
2022-08-19
Lead Sponsor
Groupe Oncologie Radiotherapie Tete et Cou
Target Recruit Count
85
Registration Number
NCT01864772
Locations
🇫🇷

Hôpital de la Dracénie, Draguignan, France

🇫🇷

Institut Gustave Roussy, Villejuif, France

Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)

First Posted Date
2005-07-22
Last Posted Date
2014-07-23
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Target Recruit Count
442
Registration Number
NCT00122460
Locations
🇬🇧

Research Site, Nottingham, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath